Trkla Co-Authors ABA Business Law Section Whitepaper Providing a Framework for Regulating Cryptocurrency and Digital Assets
13 March 2019
Partner Kathryn Trkla co-authored a first of its kind white paper on the regulation of cryptocurrencies and digital assets at the federal and state level. The white paper, “Digital and Digitized Assets: Federal and State Jurisdictional Isssues” was published by the ABA’s Business Law Section and provides background on digital and blockchain technologies as as well as analyses of the application of the Commodity Exchange Act, federal securities laws and others to transactions using cryptocurrencies and digital assets, surveys of state law regulating transactions in digital assets and cryptocurrencies and a survey of approaches in foreign jurisdictions.
Trkla is vice-chair of the ABA’s Derivatives & Futures Law Committee and chairs of the Innovative Digitized Products and Processes Subcommittee of the Business Law Section, which issued the white paper.
Trkla is vice-chair of the ABA’s Derivatives & Futures Law Committee and chairs of the Innovative Digitized Products and Processes Subcommittee of the Business Law Section, which issued the white paper.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”